Results of the economic evaluation
| Total QALYs (95% CI)† | Mean (95% CI) drug cost† | Mean (95% CI) administration and monitoring cost | Mean (95% CI) medication/medical service cost† | Total cost (95% CI)† | Total net benefits (95% CI)†‡ | |
|---|---|---|---|---|---|---|
| Discontinuous bevacizumab | 1.584 (1.538 to 1.630) | £651 (£605 to £698) | £1825 (£1708 to £1941) | £526 (£144 to £908) | £3002 (£2601 to £3403) | £28 683 (£27 707 to £29 658) |
| Continuous bevacizumab | 1.604 (1.563 to 1.645) | £1065 (£1048 to £1081) | £1952 (£1860 to £2043) | £585 (£250 to £919) | £3601 (£3259 to £3943) | £28 480 (£27 548 to £29 412) |
| Discontinuous ranibizumab | 1.582 (1.530 to 1.634) | £9229 (£8584 to £9875) | £1838 (£1724 to £1952) | £432 (£253 to £611) | £11 500 (£10 798 to £12 202) | £20 142 (£18 963 to £21 321) |
| Continuous ranibizumab | 1.608 (1.565 to 1.651) | £16 286 (£16 011 to £16 562) | £1970 (£1883 to £2057) | £334 (£215 to £452) | £18 590 (£18 258 to £18 922) | £13 576 (£12 769 to £14 383) |
| Difference: ranibizumab vs bevacizumab | Continuous: 0.004 (−0.046 to 0.054) | Continuous: £15 222 (£14 948 to £15 495)* | £16 (−£109 to £141) | Continuous: −£251 (−£604 to £102) | Continuous: £14 989 (£14 522 to £15 456)* | Continuous: −£14 904 (−£15 995 to −£13 813)* |
| Discontinuous: −0.002 (−0.064 to 0.060) | Discontinuous: £8578 (£7932 to £9225)* | Discontinuous: −£94 (−£514 to £326) | Discontinuous: £8498 (£7700 to £9295)* | Discontinuous: −£8541 (−£9939 to −£7144)* | ||
| Difference: continuous vs discontinuous | Ranibizumab: 0.026 (−0.032 to 0.085) | Ranibizumab: £7057 (£6364 to £7750)* | £130 (£20 to £239)* | Ranibizumab: −£98 (−£310 to £113) | Ranibizumab: £7090 (£6337 to £7844)* | Ranibizumab: −£6566 (−£7861 to −£5271)* |
| Bevacizumab: 0.020 (−0.032 to 0.071) | Bevacizumab: £413 (£365 to £462)* | Bevacizumab: £59 (−£438 to £556) | Bevacizumab: £599 (£91 to £1107)* | Bevacizumab: −£203 (−£1372 to £967) | ||
| Interaction | 0.006 (−0.071 to 0.084) | £6643 (£5949 to £7338)* | £5 (−£31 to £42) | −£157 (−£696 to £381) | £6491 (£5604 to £7379)* | −£6363 (−£8088 to −£4638)* |
*Significantly different from zero (p<0.05).
†Analysis allowed for interactions.
‡Net benefits equal QALYs multiplied by ceiling ratio minus costs; the net benefits shown in this table were calculated at a £20 000/QALY ceiling ratio.